Clinical Trial Update: Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan liposome with bevacizumab for platinum-resistant or recurrent ovarian, fallopian tube, or primary peritoneal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan liposome (liposomal irinotecan)

Snippet

Sponsor: Northwestern University | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-01-19